Online inquiry

IVTScrip™ mRNA-Anti-MPL, AMG 531(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ2597MR)

This product GTTS-WQ2597MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets MPL gene. The antibody can be applied in Chronic immune (idiopathic) thrombocytopenic purpurea (ITP) research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_005373.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 4352
UniProt ID P40238
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-MPL, AMG 531(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) (GTTS-WQ2597MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ14931MR IVTScrip™ mRNA-Anti-stx1B, Shigamabs®(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA Shigamabs®
GTTS-WQ4167MR IVTScrip™ mRNA-Anti-LAG3, BI-754111(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA BI-754111
GTTS-WQ3667MR IVTScrip™ mRNA-Anti-F11, BAY 1213790(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA BAY 1213790
GTTS-WQ8954MR IVTScrip™ mRNA-Anti-IL1RL2, IL2 fused to diphteria toxin(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA IL2 fused to diphteria toxin
GTTS-WQ14896MR IVTScrip™ mRNA-Anti-stx2 A-subunit, Shigamabs®(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA Shigamabs®
GTTS-WQ6701MR IVTScrip™ mRNA-Anti-SLC34A2, DNIB0600A(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA DNIB0600A
GTTS-WQ7784MR IVTScrip™ mRNA-Anti-MMP9, GS-5745(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA GS-5745
GTTS-WQ4987MR IVTScrip™ mRNA-Anti-ITGA2B&ITGB3, C4G1(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA C4G1
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW